Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
2.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med;
388(19): 1739-1754, 2023 May 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37163621
3.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38620072
4.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38620092
5.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood;
142(11): 961-972, 2023 09 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37363867
6.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood;
142(5): 446-459, 2023 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37172204
7.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood;
139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34758069
8.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood;
139(9): 1318-1329, 2022 03 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35108374
9.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood;
140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35605176
10.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Eur J Haematol;
112(5): 788-793, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38311570
11.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol;
2024 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38693677
12.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
13.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood;
138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34086865
14.
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Blood;
138(7): 544-556, 2021 08 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33735912
15.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol;
102(11): 3083-3090, 2023 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37358640
16.
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Am J Hematol;
98(12): 1856-1868, 2023 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37772428
17.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med;
380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31166681
18.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood;
135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32206772
19.
Inhibiting BTK in Chronic Lymphocytic Leukemia.
N Engl J Med;
389(1): 83-86, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37407007
20.
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
378(12): 1107-1120, 2018 Mar 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29562156